Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16265242 | 0.84 | CYP3A4 (0.37) | — | |
| SCHEMBL20883967 | 0.84 | HTR2C (0.38) | — | |
| SCHEMBL25682535 | 0.83 | — | — | |
| SCHEMBL8260982 | 0.75 | DRD2 (0.35) | — | |
| SCHEMBL27419157 | 0.74 | ADRA2A (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL16941450 | 0.74 | MB (0.38) | — | |
| SCHEMBL16941459 | 0.74 | MB (0.32) | — | |
| SCHEMBL18801624 | 0.73 | ASIC3 (0.41) | CHRNB2CHRNA4 | |
| SCHEMBL15479691 | 0.72 | — | — | |
| SCHEMBL1615698 | 0.72 | ADRA2A (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3322417-B1 | TARGETING EMOPAMIL BINDING PROTEIN (EBP) WITH SMALL MOLECULES THAT INDUCE AN ABNORMAL FEEDBACK RESPONSE BY LOWERING ENDOGENOUS CHOLESTEROL BIOSYNTHESIS | UNIV TEXAS (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023109892-A1 | COMPOUND FOR INHIBITING OR DEGRADING BRD9, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 海思科医药集团股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023104111-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-06-15 | — | — | WO | disclosed |
| US-11548894-B2 | Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3044218-B1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | UNIV TEXAS (US) | 2020-05-27 | — | — | EP | disclosed |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-03-03 | — | — | US | disclosed |
| US-10568888-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190336506-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC | 2019-11-07 | — | — | US | disclosed |
| US-20190263820-A1 | BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-08-29 | — | — | US | disclosed |
| US-10391097-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-20 | — | — | US | disclosed |
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-20 | — | — | US | disclosed |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | VTVX HOLDINGS I LLC | 2007-09-20 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007095124-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS AURORA KINASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
| US-7208601-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, LLC | 2007-04-24 | — | — | US | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
| US-20050171148-A1 | Aryl and heteroaryl compounds, compositions, methods of use | TRANSTECH PHARMA, LLC | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336506-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | PDE4A, PDE4B, TNF | CHRNB2 1497/4885CHRNA4 219/4885NPSR1 1117/4885 |
| US-10568888-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | PDE4A, PDE4B, TNF | CHRNB2 1497/4885CHRNA4 219/4885NPSR1 1117/4885 |
| US-20190263820-A1 | BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS | ACAT1, ACAT2, NPC1L1 | CHRNB2 4569/4885CHRNA4 4691/4885NPSR1 4561/4885 |
| US-11548894-B2 | Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers | ACAT1, ACAT2, NPC1L1 | CHRNB2 4569/4885CHRNA4 4691/4885NPSR1 4561/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | CHRNB2 505/4885CHRNA4 544/4885NPSR1 834/4885 |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | APC, VHL, TP53 | CHRNB2 4338/4885CHRNA4 4775/4885NPSR1 4597/4885 |
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NUDT1, PNP, NME2 | CHRNB2 4827/4885CHRNA4 4792/4885NPSR1 952/4885 |
| US-10391097-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | CHRNB2 1762/4885CHRNA4 206/4885NPSR1 3394/4885 |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | AURKC, AURKA, AURKB | CHRNB2 4441/4885CHRNA4 4620/4885NPSR1 4674/4885 |
| US-20050171148-A1 | Aryl and heteroaryl compounds, compositions, methods of use | TFPI, F3, F2 | CHRNB2 4104/4885CHRNA4 4011/4885NPSR1 2644/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | CHRNB2 505/4885CHRNA4 544/4885NPSR1 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.